Erste Group Bank Issues Negative Outlook for AbbVie Earnings

27 Oct 2026, 01:42 by Amy Steele · The Cerbat Gem

AbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Erste Group Bank cut their FY2027 earnings per share (EPS) estimates for AbbVie in a research note issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $16.28 per share for the year, down from their prior forecast of $16.34. Erste Group Bank currently has a “Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $13.93 per share.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

ABBV has been the topic of a number of other reports. HSBC boosted their price target on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Piper Sandler increased their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Argus lifted their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, UBS Group upped their price target on AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $279.86.

View Our Latest Report on ABBV

AbbVie Stock Performance

NYSE ABBV opened at $286.88 on Monday. The stock has a market cap of $506.85 billion, a price-to-earnings ratio of 26.28, a PEG ratio of 1.30 and a beta of 0.24. The business has a 50 day simple moving average of $266.18 and a 200 day simple moving average of $235.62. AbbVie has a 52-week low of $190.75 and a 52-week high of $291.40.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the business. Burk Holdings LLC bought a new stake in AbbVie in the 2nd quarter valued at $30,000. Merkkuri Wealth Advisors LLC bought a new position in AbbVie during the first quarter worth $34,000. Marquette Asset Management LLC boosted its position in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. IMG Wealth Management Inc. lifted its stake in shares of AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after buying an additional 153 shares during the last quarter. Finally, Principia Wealth Advisory LLC boosted its holdings in shares of AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the period. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

AbbVie Company Profile

(Get Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.